Use, Spending, and Prices of Adalimumab Following Biosimilar Competition

Following the introduction of the first adalimumab (Humira) biosimilar to the US market, biosimilars made up <2% of adalimumab use in 2023, and while net spending on Humira dropped by >40%, the biologic’s list price increased by 8%. This indicates that Humira’s manufacturer likely offered sizeable rebates to health plans and PBMs to retain formulary placement.